Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

MGNX – Macrogenics Inc

Float Short %

6.2

Margin Of Safety %

Put/Call OI Ratio

0.07

EPS Next Q Diff

-0.92

EPS Last/This Y

0.19

EPS This/Next Y

-0.83

Price

1.37

Target Price

3.4

Analyst Recom

2.38

Performance Q

-6.8

Relative Volume

1.32

Beta

1.53

Ticker: MGNX



19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-17MGNX1.520.200.127170
2025-11-18MGNX1.550.200.007168
2025-11-19MGNX1.420.190.117139
2025-11-20MGNX1.3750.130.006811
2025-11-21MGNX1.390.130.246805
2025-11-24MGNX1.420.080.004510
2025-11-25MGNX1.4450.070.004658
2025-11-26MGNX1.480.070.004682
2025-12-01MGNX1.470.070.004906
2025-12-02MGNX1.430.070.004942
2025-12-03MGNX1.4150.070.005047
2025-12-04MGNX1.370.070.005049
2025-12-05MGNX1.370.070.005047
2025-12-08MGNX1.3250.070.005054
2025-12-09MGNX1.3970.070.005071
2025-12-10MGNX1.390.070.005132
2025-12-11MGNX1.4130.070.005149
2025-12-12MGNX1.410.070.005152
2025-12-15MGNX1.3750.07999.995112
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1



19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-17MGNX1.5181.7- -1.71
2025-11-18MGNX1.5481.7- -1.71
2025-11-19MGNX1.4281.7- -1.71
2025-11-20MGNX1.3881.7- -1.71
2025-11-21MGNX1.3997.6- -0.89
2025-11-24MGNX1.4297.6- -0.89
2025-11-25MGNX1.4597.6- -0.89
2025-11-26MGNX1.4797.6- -0.89
2025-12-01MGNX1.4797.6- -0.89
2025-12-02MGNX1.4297.6- -0.89
2025-12-03MGNX1.4097.6- -0.89
2025-12-04MGNX1.3897.6- -0.89
2025-12-05MGNX1.3797.6- -0.89
2025-12-08MGNX1.3397.6- -0.89
2025-12-09MGNX1.3997.6- -0.89
2025-12-10MGNX1.3997.6- -0.89
2025-12-11MGNX1.4297.6- -0.89
2025-12-12MGNX1.4097.6- -0.89
2025-12-15MGNX1.3797.6- -0.89
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1



19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-17MGNX2.003.486.13
2025-11-18MGNX2.003.486.13
2025-11-19MGNX2.003.486.13
2025-11-20MGNX2.003.486.13
2025-11-21MGNX2.003.486.13
2025-11-24MGNX2.00-3.556.13
2025-11-25MGNX2.00-3.556.13
2025-11-26MGNX2.00-3.556.13
2025-12-01MGNX2.00-3.566.13
2025-12-02MGNX2.00-3.566.13
2025-12-03MGNX2.00-3.566.13
2025-12-04MGNX2.00-3.566.13
2025-12-05MGNX2.00-3.566.13
2025-12-08MGNX2.00-3.646.13
2025-12-09MGNX2.00-3.646.13
2025-12-10MGNX2.00-3.646.20
2025-12-11MGNX2.00-3.646.20
2025-12-12MGNX2.00-3.646.20
2025-12-15MGNX2.00-3.666.20
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="MGNX" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS​

0.27

Avg. EPS Est. Current Quarter

-0.02

Avg. EPS Est. Next Quarter

-0.66

Insider Transactions

2

Institutional Transactions

-3.66

Beta

1.53

Average Sales Estimate Current Quarter

27

Average Sales Estimate Next Quarter

9

Fair Value

Quality Score

35

Growth Score

28

Sentiment Score

77

Actual DrawDown %

96.2

Max Drawdown 5-Year %

-97

Target Price

3.4

P/E

Forward P/E

PEG

P/S

0.68

P/B

1.29

P/Free Cash Flow

EPS

-1.21

Average EPS Est. Cur. Y​

-0.89

EPS Next Y. (Est.)

-1.72

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-59.46

Relative Volume

1.32

Return on Equity vs Sector %

-140.3

Return on Equity vs Industry %

-125.2

EPS 1 7Days Diff

1.3

EPS 1 30Days Diff

0.83

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”MGNX” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”MGNX” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”MGNX” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”MGNX” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”MGNX” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”MGNX” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”MGNX” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
MacroGenics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 341
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
stock quote shares MGNX – Macrogenics Inc Stock Price stock today
news today MGNX – Macrogenics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MGNX – Macrogenics Inc yahoo finance google finance
stock history MGNX – Macrogenics Inc invest stock market
stock prices MGNX premarket after hours
ticker MGNX fair value insiders trading